Project Grant R43DK122846

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a novel Diabetes Targeted Dual Neuromodulation (TDN) therapy. The $345,650 grant will fund a Phase I feasibility study by Reshape Lifesciences Inc., a small business joint venture, to validate the hypothesis that decreasing the amplitude of the high frequency...

This National Science Foundation (NSF) Division of Computer and Network Systems Project Grant award totaling $839,998 to Michigan State University supports the development of a novel wireless optoelectronic implant system for closed-loop control of bi-hormone (insulin and glucagon) secretion from genetically modified islet organoids. The goal is to create an implantable, wireless, and battery-free device that can precisely regulate hormone levels to manage type 1 diabetes. The project involves...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3,565,780 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a groundbreaking high-frequency trans-spinal magnetic stimulation (HF-TSMS) system for the non-invasive treatment of neuropathic pain. The funded project aims to create an HF-TSMS tool that can target neural pathways involved in...

This $335,410 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a needle-free microneedle array patch (MAP) for delivering a GLP-1 receptor agonist to treat type 2 diabetes. The grant recipient, Vaxess Technologies, Inc., is a biotechnology company specializing in innovative MAP technologies for drug and vaccine...

Teliatry Inc. received a $768,138 project grant award from the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering to develop a minimally invasive, single incision, rechargeable spinal cord stimulation system for chronic pain management. The grant was awarded under the Discovery and Applied Research for Technological Innovations to Improve Human Health program. Through this award, Teliatry will engineer the world's smallest (0.75cc), most cost-effective...

The National Institutes of Health National Institute of Neurological Disorders and Stroke awarded an $11.2 million project grant to the University of Pittsburgh to define the mechanisms of pain relief associated with dorsal root ganglion and spinal cord stimulation. This three-year grant will support research under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to advance understanding of neuromodulatory devices for chronic pain treatment. The University will conduct preclinical...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $970,052 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Backstop Neural, Inc. The grant aims to demonstrate the feasibility of a novel paddle-type epidural stimulation lead to relieve chronic arm and neck pain. Backstop Neural will design and fabricate a 16-channel, 0.2 mm thick human-sized softening paddle lead that can conform to the spinal cord, providing positional stability and...

This $14.2 million project grant from the National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, will fund research from September 2022 to August 2025 under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The Massachusetts General Hospital will investigate the mechanisms by which spinal cord stimulation reduces pain, with the goal of improving device design and patient selection. Researchers will apply specialized nerve...

This $319,990 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund a 12-week randomized controlled trial. The trial will enroll 72 adult participants with type 2 diabetes mellitus (T2DM) to compare the efficacy of medical nutrition therapy personalized using continuous glucose monitoring (CGM) feedback versus three control interventions. The...

The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...